ArticleScientific reports2025
Alterations in iron status predict cardiac response to blood transfusion in β-thalassemia major.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advancements in the management of thalassemia, cardiac complications still represent a leading cause of disability and death. Heart dysfunction, although mainly related to myocardial iron overload (IO), might already manifest when the homeostasis of circulating iron species is altered. This study aimed to investigate the presence of heart function changes in relation to scheduled blood transfusions (BT) in transfusion-dependent thalassemic patients, to identify alterations in cardiac function early after BT or within a 7-10 days interval. Twenty patients (8 females; average age 41.65 years), followed at the Center for Hereditary Anemias, University Hospital of Modena, were enrolled to perform an echocardiographic evaluation (ECE) before scheduled BT (T0), a targeted ECE immediately after the transfusion (Tearly), and a targeted ECE 7-10 days thereafter (Tlate). Medical history, biochemical data, and parameters related to iron status including serum levels of labile plasma iron (LPI), non-transferrin-bound iron (NTBI), and 3 year-average serum ferritin, were collected to assess predictors of transfusion-related cardiac changes. Global longitudinal strain (GLS) at baseline was worse, on average, in patients with higher ferritin or lower serum calcium; early post-transfusion GLS improved significantly in patients with ferritin>1500 ng/mL or albumin-corrected calcium [Formula: see text] mg/dL, whereas it remained stable in control groups. Notably, several early post-transfusion changes could be consistently predicted by variables related to iron homeostasis or transfusion status. Cardiac MRI T2* showed moderate IO in only one patient. In conclusion, β-thalassemic patients with hyperferritinemia or hypocalcemia are likely those who benefit most from BT in terms of systolic function. Even in the absence of overt myocardial IO, alterations in circulating iron status predict early dysfunctions in cardiac response after scheduled blood transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.